Algernon Pharmaceuticals Balance Sheet Health
Financial Health criteria checks 5/6
Algernon Pharmaceuticals has a total shareholder equity of CA$437.3K and total debt of CA$0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are CA$4.0M and CA$3.5M respectively.
Key information
0%
Debt to equity ratio
CA$0
Debt
Interest coverage ratio | n/a |
Cash | CA$76.28k |
Equity | CA$437.32k |
Total liabilities | CA$3.52m |
Total assets | CA$3.95m |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: AGN's short term assets (CA$123.2K) do not cover its short term liabilities (CA$3.5M).
Long Term Liabilities: AGN has no long term liabilities.
Debt to Equity History and Analysis
Debt Level: AGN is debt free.
Reducing Debt: AGN has not had any debt for past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: AGN has sufficient cash runway for 1 months based on last reported free cash flow, but has since raised additional capital.
Forecast Cash Runway: AGN is forecast to have sufficient cash runway for 0 months based on free cash flow estimates, but has since raised additional capital.